{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-032826","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.110048+00:00","generated_at":"2026-06-04T15:50:07.602145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenaya reports Q4 net loss $29.9M; cash $104.6M; TN-201 data and TN-401 dosing expected H2 2024","bullets":["Net loss $29.9M ($0.40/sh) Q4 2023; full year net loss $124.1M ($1.68/sh).","Cash, equivalents and investments $104.6M at Dec 31, 2023; Feb 2024 financing adds $46.5M net, extending runway into H2 2025.","Initial safety and biomarker data from MyPeak-1 Phase 1b of TN-201 for MYBPC3 HCM expected H2 2024; first patient dosed Oct 2023.","RIDGE-1 Phase 1b of TN-401 for PKP2 ARVC on track to dose first patient H2 2024; FDA Fast Track granted Nov 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-032826","json":"https://secwatch.observer/filing/0000950170-24-032826.json","markdown":"https://secwatch.observer/filing/0000950170-24-032826.md","text":"https://secwatch.observer/filing/0000950170-24-032826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024032826/0000950170-24-032826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024032826/tnya-20240318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:50:07.602145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea8bc7c4b235ea3d6cb679ca31f32a30e9c20a88","claim":"Tenaya Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, n, EPS $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or.","evidence_excerpt":"Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or $1.68 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024032826/0000950170-24-032826-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, n"},{"label":"EPS","value":"$0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}